Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia

Thomas, Natalie; Gurvich, Caroline; Hudaib, Abdul Rahman; Gavrilidis, Emorfia; Kulkarni, Jayashri

doi:10.1016/j.psychres.2019.112510

Cited by 11 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same group investigated the role played in this association by the follicle stimulating hormone/luteinizing hormone (FSH/LH) ratio, but the results were inconclusive [73]. A recent study supports the identification of hormonal phenotypes among women with schizophrenia, suggesting that it may help to improve existing treatments and implement personalized-medicine strategies that address the heterogeneity seen in schizophrenia [10].…”

Section: Treatment and Health Care Needs In Women With Schizophrenia mentioning

confidence: 99%

“…Clinical practice guidelines for schizophrenia rarely identify sex-specific requirements [8] although attention is being paid in the more recent literature to sexually dimorphic features of drug efficacy and tolerability [9]. Hormonal effects on drugs have led to a more general appreciation of hormonal influence on the dimorphic expression of schizophrenia in women and men [10]. For instance, recent studies have found that levels of follicle-stimulating hormone (FSH), dehydroepiandrosterone, and luteinizing hormone (LH) are closely associated with the severity of schizophrenia symptoms [10].…”

Section: Introduction: Health Care For Women With Schizophreniamentioning

confidence: 99%

“…Hormonal effects on drugs have led to a more general appreciation of hormonal influence on the dimorphic expression of schizophrenia in women and men [10]. For instance, recent studies have found that levels of follicle-stimulating hormone (FSH), dehydroepiandrosterone, and luteinizing hormone (LH) are closely associated with the severity of schizophrenia symptoms [10].…”

Section: Introduction: Health Care For Women With Schizophreniamentioning

confidence: 99%

See 2 more Smart Citations

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes

González-Rodríguez

Guàrdia²,

Pedrero

et al. 2020

IJERPH

View full text Add to dashboard Cite

Women with schizophrenia show sex-specific health needs that differ according to stage of life. The aim of this narrative review is to resolve important questions concerning the treatment of women with schizophrenia at different periods of their life—paying special attention to reproductive and post-reproductive stages. Review results suggest that menstrual cycle-dependent treatments may be a useful option for many women and that recommendations re contraceptive options need always to be part of care provision. The pregnancy and the postpartum periods—while constituting vulnerable time periods for the mother—require special attention to antipsychotic effects on the fetus and neonate. Menopause and aging are further vulnerable times, with extra challenges posed by associated health risks. Pregnancy complications, neurodevelopmental difficulties of offspring, cancer risk and cognitive defects are indirect results of the interplay of hormones and antipsychotic treatment of women over the course of the lifespan. The literature recommends that health promotion strategies need to be directed at lifestyle modifications, prevention of medical comorbidities and increased psychosocial support. Careful monitoring of pharmacological treatment has been shown to be critical during periods of hormonal transition. Not only does treatment of women with schizophrenia often need to be different than that of their male peers, but it also needs to vary over the course of life.

show abstract

Section: Treatment and Health Care Needs In Women With Schizophrenia mentioning

confidence: 99%

Section: Introduction: Health Care For Women With Schizophreniamentioning

confidence: 99%

Section: Introduction: Health Care For Women With Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes

González-Rodríguez

Guàrdia²,

Pedrero

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Understanding the contribution of sex and hormones may offer new avenues for personalized treatment and prevention of these disorders. Kulkarni and her collaborators [ 116 ] used the positive-and-negative-syndrome-scale (PANSS) and the Montgomery-Asberg-Depression-Rating Scale (MADRS) to determine the influence of various hormones (estradiol, progesterone, follicular stimulating hormone (FSH), luteinising hormone (LH), and dehydroepiandrosterone (DHEA)) on the psychopathology of 45 women with schizophrenia. The mean age of the sample was 46 and hormone levels were collected over 12-weeks.…”

Section: Resultsmentioning

confidence: 99%

Stratification by Sex and Hormone Level When Contrasting Men and Women in Schizophrenia Trials Will Improve Personalized Treatment

Seeman

González-Rodríguez

2021

JPM

View full text Add to dashboard Cite

Background: Sex and gender differences have been reported in the prevalence, expression, treatment response, and outcome of schizophrenia, but most reports are based on relatively small samples that have not been stratified for the impact of sex hormone levels. This literature review aims to show how women’s hormone levels can impact the results of male/female comparisons. Methods: This is a narrative review of data from publications of the last decade. Results: Epidemiologic evidence, reports of the impact of hormones on cognition, results of sexually dimorphic responses to treatment, and male/female trajectories of illness over time all suggest that female hormone fluctuations exert major effects on male/female differences in schizophrenia. Conclusions: Information on hormonal status in women participants is rarely available in clinical studies in schizophrenia, which makes male/female comparisons largely uninterpretable. These are the current challenges. Opportunities for individualized treatment are growing, however, and will undoubtedly result in improved outcomes for both women and men in the future.

show abstract

“…Estrogen, androgen, and progesterone receptors Gonadosteroid-binding receptors are among the NRs with implications in PDs supported by strong and multilevel evidence. Women who are in their peak estrogen-producing years or transitioning to menopause are at an elevated risk of developing affective disorders, as are women who are experiencing hormonal fluctuations, e.g., during menstrual periods and postpartum [140] . Sex-biases characterize PDs in general, and altered levels of progesterone and androgens have been reported in SZ and estrogen levels in numerous PDs [141] .…”

Section: Genetic Epidemiological Empirical and Pharmacological Evidence Highlight Distinct Psychiatryrelevant Nuclear Receptor-mediated Smentioning

confidence: 99%

Large-scale genomic data-mining implicates dysregulated nuclear receptor-mediated signaling in mental illness

Donskov¹

2021

jtgg

View full text Add to dashboard Cite

Aim: Mental illness comprises a group of heterogeneous conditions attributable to a complex interplay between hereditary and environmental components. Acting at the interface between environmental stimuli and their genomic actions, nuclear receptors (NRs) appear uniquely suited to facilitate gene-environment interactions in the context of mental health. Genetic disruptions to the NR transcriptomic complex (NTC) give rise to neuropsychiatric pathologies, and epidemiological risks involving a steroid response are among the most replicated in psychiatry. Importantly, pharmacological targeting of NR-mediated signaling is clinically effective in the treatment of psychiatric disorders. Here, we systematically interrogated large-scale deposited data to provide a comprehensive evaluation of the genomic NTC risk burden in mental illness.Methods: Utilizing data from large, recent genome-, exome-, and methylome-wide association studies on psychiatric disorders, we assessed the representation of NTC genes among top associated loci and tested the gene set associations for NTC and NR target genes using GWAS summary statistics. Through data mining and transcriptomic profiling of NR-mediated signaling in the diseased and healthy human brain, we categorized psychiatry-relevant NTC gene networks.

show abstract

Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia

Cited by 11 publications

References 50 publications

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes

Stratification by Sex and Hormone Level When Contrasting Men and Women in Schizophrenia Trials Will Improve Personalized Treatment

Large-scale genomic data-mining implicates dysregulated nuclear receptor-mediated signaling in mental illness

Contact Info

Product

Resources

About